Ferdinand (Ferd) Massari, M.D., is an accomplished biopharmaceutical executive with a proven record of building and leading high-performing organizations that consistently exceed expectations. Over his career, Ferd has played a pivotal role in the approval of multiple therapies that have improved millions of lives worldwide. His leadership spans the full biopharma value chain, with executive experience as CEO, President of R&D, Chief Medical Officer, and Director of Marketing. Most recently, Ferd served as CEO of ProTgen, a biotechnology startup developing progenitor T-cell therapies for various cancers. Before ProTgen, Ferd held senior executive roles at multiple early-stage biotech companies, including Chief Medical Officer at Deep Genomics and Coley Pharmaceuticals, and President of R&D at Kintai Therapeutics.
Earlier in his career, Ferd served in key leadership positions at major global pharmaceutical companies, including Vice President and Global Head of Clinical and Medical Affairs in the Rare Diseases division at Shire, Vice President of Worldwide Medical Affairs at Pfizer, and Vice President of Clinical Research at Pharmacia. He began his career at Merck, where he was the first physician to serve as Director of Marketing after years of leading the HIV team in Clinical Research.
Ferd earned his medical degree from Sidney Kimmel Medical College (Jefferson) in Philadelphia under a National Health Service Corps (NHSC) scholarship. He completed his training in Internal Medicine and completed a fellowship in Allergy & Immunology at the National Institute of Allergy and Infectious Diseases (NIAID), where he conducted research on the immunopathogenesis of HIV infection in the laboratory of Dr. Anthony S. Fauci under a National Research Service Award (NRSA).
